We are a team with a long-standing interest in how blood vessels in the kidney contribute to both health and disease. Over the years, we have combined methods ranging from electron microscopy and in vivo models of glomerular injury to modern single-cell and spatial transcriptomics. These approaches allow us to map the heterogeneity of endothelial cells in health and in conditions such as diabetic nephropathy. I am particularly interested in how molecular pathways such as Tie2/angiopoietin signalling and endothelial–podocyte cross-talk can be targeted to preserve capillary integrity, slow chronic kidney disease progression, and ultimately protect patients from kidney failure.
Our translational ambition is to move beyond understanding mechanisms toward developing new treatments. It is an ambition to utilize discoveries to create therapies for kidney and cardiovascular diseases. Our work stands at the interface of basic vascular biology and clinical nephrology. By bridging these fields, we hope to redefine kidney disease as a disorder of the entire vascular niche and to contribute to therapies that address the root causes of organ damage, not only its symptoms.